- $7.56bn
- $8.93bn
- $2.82bn
- 73
- 53
- 64
- 67
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Premiums Earned | |||||
Net Investment Income | |||||
Realized & Unrealized Gains / Losses | |||||
Total Revenue | 2,054 | 2,222 | 2,710 | 2,720 | 2,816 |
Losses, Benefits, and Adjustments | |||||
Amortization of Policy Acquisition Costs | |||||
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,548 | 1,686 | 2,036 | 2,073 | 2,037 |
Operating Profit | 506 | 536 | 674 | 647 | 778 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 477 | 507 | 644 | 620 | 752 |
Provision for Income Taxes | |||||
Net Income After Taxes | 366 | 386 | 476 | 467 | 577 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 366 | 386 | 477 | 472 | 577 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 365 | 384 | 475 | 470 | 574 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 8.64 | 9.65 | 13.6 | 13.5 | 15.9 |
Dividends per Share |